Literature DB >> 15209627

Ethnic and cultural determinants influence risk assessment for hepatitis C acquisition.

Anouk Dev1, Vijaya Sundararajan, William Sievert.   

Abstract

BACKGROUND AND AIM: In the developed world hepatitis C virus (HCV) infection is predominantly associated with sharing contaminated equipment between injecting drug users (IDU). In developing countries inadequately sterilized medical equipment, transmission of infected blood and cultural practices have been implicated. Accurate risk factor assessment is essential for education targeted at risk reduction in culturally diverse populations.
METHODS: Ninety Australian-born Caucasians and 72 South-east Asian (SEA) HCV patients attending a Melbourne hospital liver clinic completed a questionnaire which assessed risk factor profile, perceived risk factors, knowledge of risk factors and methods to minimize transmission. Medical records were audited to identify doctor assessment of risk factors.
RESULTS: Risk factors in Caucasians were IDU, body piercing and tattooing (89%, 47% and 32%, respectively). Risk factors in SEA patients were injection therapy, dental therapy and surgery (89%, 70% and 38%, respectively). Most Caucasian patients (94%) correctly identified their mode of acquisition compared with 33% of SEA patients (P < 0.0001). Accurate risk factor documentation in medical records was more common in Caucasians (96 vs 32%; P < 0.0001). The majority of patients identified blood-to-blood and sexual/vertical transmission as important modes of acquisition. However, 33% of SEA patients believed transmission occurred through food, water and poor hygiene and 80% did not identify therapeutic injection or traditional medical practices as risk factors. Education provided to SEA patients did not address less well established routes of transmission.
CONCLUSIONS: Ethnicity influences perception and knowledge of risk factors. Improved assessment of risk factors in high-risk ethnic groups is needed. Education should be culturally appropriate and address the concerns of all populations with HCV. Copyright 2004 Blackwell Publishing Asia Pty Ltd

Entities:  

Mesh:

Year:  2004        PMID: 15209627     DOI: 10.1111/j.1440-1746.2004.03381.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  6 in total

1.  A comparative study of patients' knowledge about hepatitis C in the United States and in urban and rural China.

Authors:  Elizabeth Wu; Xisui Chen; Zhe Guan; Claudia Cao; Huiying Rao; Bo Feng; Melvin Chan; Sherry Fu; Andy Lin; Lai Wei; Anna S Lok
Journal:  Hepatol Int       Date:  2014-07-31       Impact factor: 6.047

2.  Risk factors, genotype 6 prevalence, and clinical characteristics of chronic hepatitis C in Southeast Asian Americans.

Authors:  Nghia H Nguyen; Philip Vutien; Huy N Trinh; Ruel T Garcia; Long H Nguyen; Huy A Nguyen; Khanh K Nguyen; Mindie H Nguyen
Journal:  Hepatol Int       Date:  2010-04-09       Impact factor: 6.047

Review 3.  Illness perceptions and explanatory models of viral hepatitis B & C among immigrants and refugees: a narrative systematic review.

Authors:  John A Owiti; Trisha Greenhalgh; Lorna Sweeney; Graham R Foster; Kamaldeep S Bhui
Journal:  BMC Public Health       Date:  2015-02-15       Impact factor: 3.295

4.  Racial Disparities in Treatment Rates for Chronic Hepatitis C: Analysis of a Population-Based Cohort of 73,665 Patients in the United States.

Authors:  Philip Vutien; Joseph Hoang; Louis Brooks; Nghia H Nguyen; Mindie H Nguyen
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

5.  Risk Factors for Loss to Follow-Up among People Who Inject Drugs in a Risk Reduction Program at Karachi, Pakistan. A Case-Cohort Study.

Authors:  Rab Nawaz Samo; Ajmal Agha; Sharaf Ali Shah; Arshad Altaf; Ashraf Memon; Meridith Blevins; Han-Zhu Qian; Sten H Vermund
Journal:  PLoS One       Date:  2016-02-03       Impact factor: 3.240

Review 6.  Animal Models Used in Hepatitis C Virus Research.

Authors:  Keith A Berggren; Saori Suzuki; Alexander Ploss
Journal:  Int J Mol Sci       Date:  2020-05-29       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.